Treace Medical Concepts

TMCI

Market cap $403M

PONTE VERDE, Fla., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced it will highlight new product innovations and present new interim data for the ALIGN3D™ and MTA3D™ clinical studies at the American Orthopaedic Foot & Ankle Society (AOFAS) Annual Meeting 2025 in Savannah, Georgia from September 10-13, 2025.

Treace Medical Concepts, Inc. (NASDAQ:TMCI ) Investor Day Call September 3, 2025 9:00 AM EDT Company Participants John Treace - Founder, Chairman & CEO Sean Scanlan - Chief Innovation Officer Conference Call Participants William DeCarbo Mark Easley Holly Johnson Jonathan Kaplan Ryan Zimmerman - BTIG, LLC, Research Division Richard Newitter - Truist Securities, Inc., Research Division Arthur Weise Danielle Antalffy - UBS Investment Bank, Research Division Lilia-Celine Lozada - JPMorgan Chase & Co, Research Division Anton Heldmann - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation John Treace Founder, Chairman & CEO Good morning, everybody. We're going to go ahead and get started.

Treace Medical Concepts, Inc. (NASDAQ:TMCI ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants John T. Treace - Founder, Chairman & CEO Mark L.

Treace Medical (TMCI) Q2 Revenue Up 7%

Treace Medical Concepts (TMCI) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.34 per share a year ago.

PONTE VEDRA, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today reported financial results for the second quarter ended June 30, 2025.

PONTE VEDRA, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced plans to host an investor day at 9:00 am E.T. on September 3, 2025, in New York, New York. The event will include presentations by members of management and experienced surgeon users, highlighting their experiences with the expanded technology portfolio.

PHILADELPHIA, July 01, 2025 (GLOBE NEWSWIRE) -- Maison Solutions Inc. (NASDAQ: MSS) Class Action Survives Motion to Dismiss:

NEW YORK , June 11, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Treace Medical Concepts, Inc. (NASDAQ: TMCI)  breached their fiduciary duties to shareholders.  According to a federal securities lawsuit, Insiders at Treace Medical caused the company to misrepresent or fail to disclose (1) competition impacted the demand for and utilization of its primary product, the Lapiplasty 3D Bunion Correction System; (2) as a result, Treace Medical's revenue declined, and the Company needed to accelerate its plans to offer a product that served as an alternative to osteotomy (a surgical procedure involving the cutting and realignment of a bone to improve its position or function); and (3) positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

NEW YORK, NY / ACCESS Newswire / June 10, 2025 / If you suffered a loss on your Treace Medical Concepts, Inc. (NASDAQ:TMCI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/treace-medical-concepts-inc-lawsuit-submission-form-2?prid=152492&wire=1&utm_campaign=2 or contact Joseph E. Levi, Esq.